This work identifies a novel regulatory axis (LncRNA-IH → TGF-β1 → ZEB1) and highlights LncRNA-IH as a potential therapeutic target to improve post-MI outcomes by inhibiting fibroblast activation. This evidence concerns the gene ZEB1 and myocardial infarction.